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Abstract
Background Both the US FDA and the European
Medicines Agency (EMA) have approved aripiprazole for
use in adolescents for specific indications. Given the
assumed favorable side-effect profile of aripiprazole, its
use in children and adolescents has increased for both
official and off-label indications (anxiety disorders, eating
disorders, personality disorders). However, several cases of
children and adolescents with new-onset extrapyramidal
symptoms (EPS) after commencing treatment with arip-
iprazole have been reported, and a more systematic
appraisal of this possible risk is lacking.
Objective We conducted a systematic review and a meta-
analysis to assess the evidence for acute EPS (acute dys-
tonia, akathisia, Parkinsonism) associated with the use of
aripiprazole in children and adolescents.
Method We searched the MEDLINE and Embase data-
bases (2003–10 April 2016) for clinical trials in pediatric
patients (aged 0–18 years) using the keywords ‘aripipra-
zole’ (regardless of the formulation) and ‘extrapyramidal
symptoms’. We evaluated the abstracts of papers using the
following exclusion criteria: (1) study design: case report,
letter to the editor, editorial, or poster presentation data; (2)
unrelated PICOS (population, intervention, comparators,
outcomes, study) structure. We performed a meta-analysis,
in which we used effect sizes with 95 % confidence
intervals (CIs). To examine the homogeneity of the effect
size distribution, we used a Q-statistic. When we observed
heterogeneity in effect sizes, we assessed the possible
influence of moderator variables (age and sex, mean dose,
study duration, and method of measuring EPS incidence)
and evaluated the suitability of either a fixed or a random
model. Finally, we assessed the incidence of EPS in chil-
dren and adolescents treated with aripiprazole compared
with placebo.
Results An initial search via PubMed and Embase yielded
328 hits. A manual search of the reference lists of review
papers revealed seven additional relevant articles. We
included 41 studies, with 2114 pediatric patients, in the
meta-analysis. For the analysis of the mean incidence of
EPS, data were provided by 24 studies, with a total of 1446
pediatric patients. Meta-analysis revealed a mean EPS
incidence of 17.1 % (95 % CI 0.128–0.223). In terms of the
incidence of various extrapyramidal side effects, overall,
no significant effects of age, sex, mean dose, study dura-
tion, or measuring method could be demonstrated. The side
effects ‘EPS’, ‘parkinsonism’, and ‘tremor’ were signifi-
cantly more common in children and adolescents treated
with aripiprazole than in those treated with placebo.
Conclusion Our meta-analysis provides evidence for a
non-negligible incidence of acute EPS in children and
adolescents treated with aripiprazole. Although the study
has several limitations and further investigation is needed,
these findings may help clinicians make more balanced
treatment choices and more closely monitor the use of this
drug in youth.
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Key Points
In light of recent concerns about extrapyramidal
symptoms (EPS) as a potential side effect of
aripiprazole, we conducted a meta-analysis to assess
the incidence of EPS in children and adolescents.
We found a mean incidence of 17.1 % (95 %
confidence interval 0.128–0.223).
This finding highlights the importance of considerate
prescription of aripiprazole in youth.
1 Introduction
The US FDA has approved the use of aripiprazole in
adolescents (aged 13–17 years) with schizophrenia, in
pediatric patients (aged 10–17 years) with manic or mixed
episodes associated with a bipolar I disorder (both as
monotherapy and as an adjunct to lithium or valproate
[2, 3]), and for the treatment of irritability associated with
autistic disorder in pediatric patients (aged 6–17 years) [4].
In Europe, the use of aripiprazole is approved by the
European Medicines Agency (EMA) for the treatment of
schizophrenia in adolescents aged C15 years and for the
treatment of moderate to severe manic episodes associated
with a bipolar I disorder for up to 12 weeks in adolescents
aged C13 years. The EMA does not recommend the use of
aripiprazole in patients aged \13 years because of the
increased risk of adverse events associated with the drug in
younger patients [1].
Aripiprazole is an atypical antipsychotic. The efficacy of
antipsychotics in general is thought to be mediated mainly
by D2 dopamine receptor antagonism in the mesolimbic
brain region, targeting pathways that at least partly mediate
psychosis, mania, tics, and aggression. In addition, atypical
antipsychotics exert pharmacodynamic activity at other
receptors. The efficacy, safety, and tolerability of each
individual antipsychotic can ultimately be explained by its
unique binding properties and their interactions with
dopaminergic, noradrenergic, serotonergic, histaminergic,
and cholinergic receptors. For example, dopaminergic
pathways mediating motor movements, prolactin secretion,
cognition, and motivation can be influenced, resulting in
adverse effects such as extrapyramidal symptoms (EPS),
increased prolactin levels, and neurolepsis (characterized
by apathy, anhedonia, amotivation, and social withdrawal).
Another example is the undesired blockade of histaminer-
gic H1 receptors, leading to weight gain [5, 6].
The FDA recently sent a warning of new potential side
effects: compulsive or uncontrollable urges to gamble,
binge eat, shop, and have sex have been reported with the
use of aripiprazole. These will be added to the drug labels
and the patient medication guides as potential side effects
for all aripiprazole products [79].
The incidence of side effects can vary substantially,
depending on, for example, differences in antipsychotic
dose. Age and development can also influence suscepti-
bility to adverse effects. Children and adolescents treated
with aripiprazole are more vulnerable than older patients to
weight gain and other metabolic side effects [8]. In general,
younger patients (aged\20 years) are also more likely to
experience EPS [7].
EPS can manifest early or in the longer term after
commencing antipsychotic treatment. Tardive dyskinesia is
one of the late variants of EPS. Early EPS can be further
divided into three categories: (acute) dystonia, (acute)
akathisia, and parkinsonism (tremor, bradykinesia/hypoki-
nesia, rigidity) [7]. Dystonia usually manifests early in
therapy [3], fluctuates with stress and relaxation [9], and is
characterized by abnormal and sustained contractions of
muscle groups in the head, neck, back, eyes, and limbs
[10]. This may result in torticollis, cramps, and pain in the
head, neck, and back; oculogyric crises; and potentially
lethal respiratory stridor if pharyngeal or laryngeal mus-
culature is affected. Parkinsonism also occurs early after
administration of antipsychotic drugs. Akathisia may begin
early in treatment, but the onset may also be delayed [11].
Akathisia is defined by the subjective feeling of restless-
ness, often accompanied by the urge to move and inability
to sit still [9, 10]. The symptoms more often affect the
lower extremities and vary with stress and arousal [9].
Atypical antipsychotics seem to be an attractive alternative
to typical antipsychotics because of the promise of fewer
EPS for equal efficacy [5, 12]. Within the group of atypical
antipsychotics, aripiprazole is considered to lead to rela-
tively minimal metabolic side effects and prolactin
increases [3, 4, 8, 11, 13]. The perceived favorable risk
profile has led to an increase in the use of aripiprazole in
youth for both official and off-label indications (anxiety,
eating, personality disorders, Gilles de la Tourette syn-
drome, etc.) [14, 15].
However, some authors have questioned the assumed
favorable EPS profile of atypical antipsychotics as a group
relative to the typical antipsychotics (prototype: haloperi-
dol) [9, 13]. Such reservations are relevant to children,
adolescents, and adults. Given this, and the increased use of
aripiprazole in pediatric patients, we wished to investigate
the risk of children and adolescents developing (acute) EPS
when treated with aripiprazole. Therefore, we conducted a
meta-analysis to assess the evidence for acute EPS asso-
ciated with the use of the drug in this patient group.
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2 Methods
2.1 Search
We searched the English, French, and Dutch literature via
PubMed and Embase from 2003 until 10 April 2016. A first
explorative search did not reveal many relevant hits, so we
imposed minimum constraints on our eligibility criteria,
e.g. we did not define comparator treatments in advance or
limit our search to one manifestation of EPS.
Eligibility criteria are described according to the PICOS
structure (population, intervention, comparators, outcomes,
study design). Specifically, published studies in human
subjects were eligible if the following criteria were met:
• Population: children and adolescents aged \18 years
were considered.
• Interventions/comparisons: treatment with aripiprazole
(regardless of the formulation) was considered; com-
parator treatments were not defined in advance.
• Outcomes: to account for all manifestations of (acute)
EPS, we used the key term ‘‘extrapyramidal
symptoms’’.
2.2 Study Selection
We used the following exclusion criteria to evaluate the
abstracts of papers identified by the initial search for rel-
evance to the study question: (1) study design: case report,
case series, letter to the editor, editorial, or data solely
presented by means of a poster presentation; (2) unrelated
PICOS structure, e.g. another antipsychotic or a combina-
tion therapy was studied, the study focused on other side
effects or on efficacy of treatment rather than on safety and
tolerability, or the (mean) age of the study participants was
[18 years. We also manually searched the reference lists
of review papers to ensure all relevant studies were
included.
This study was conducted in accordance with the Dec-
laration of Helsinki and approved by the Ethical Guidance
Committee of the Faculty of Medicine, KU Leuven,
Belgium.
2.3 Methodological Quality Assessment
We used the Jadad scale [80] to assess the quality of ran-
domized studies. Depending on the description of the
randomization method, double blinding, and the descrip-
tion of dropouts and withdrawals, an overall quality score
ranging from 0 (weakest score) to 5 (strongest score) was
assigned to the individual studies. We only included studies
scoring C3 points in our analysis, as studies with this score
are usually considered of adequate trial quality.
Although the use of scales to assess study quality is
common and appealing because of their simplicity, some
disadvantages need to be taken into account. The Cochrane
Handbook for Systematic Reviews of Interventions alerts us
to some of the risks inherent to the use of scales to assess
quality. For example, ‘‘calculating a summary score
inevitably involves assigning ‘weights’ to different items in
the scale,’’ which makes it ‘‘difficult to justify the weights
assigned’’ and scales ‘‘are less likely to be transparent to
users of the review’’ [81]. Consequently, the authors
express their preference for a detailed description (i.e.,
‘‘how each trial was rated on each criterion’’) of the quality
assessment approach.
Several instruments have been developed to assess the
methodological quality of non-randomized studies of
interventions. Again, the Cochrane Handbook for System-
atic Reviews of Interventions advises review authors to use
these instruments with caution [81]. We were unable to find
a tool appropriate for use with all the different designs in
the non-randomized studies included in our meta-analysis.
Therefore, we provide the reader with a description of
quality items for each study (see the Electronic Supple-
mentary Material [ESM]). Based on the work of Gearing
et al. [82] and Vassar and Holzmann [83], we identified six
domains underpinning the methodological quality assess-
ment of retrospective chart reviews: research question,
sample, exclusion criteria, operationalization of the con-
cept (EPS), data abstraction, and confidentiality issues,
and/or ethical considerations. The methodological quality
assessment of the other studies was based on the New-
castle–Ottawa Scale (the version for cohort studies) [84]
and the quality rating criteria mentioned by Forbes and
Griffiths [85]. Finally, information regarding potential
sources of support in the included studies is listed in the
ESM.
2.4 Data Extraction
We extracted the following information: study charac-
teristics (year of publication, study design, study dura-
tion), study population characteristics (main diagnosis
according to the Diagnostic and Statistical Manual of
Mental Disorders, fourth edition, text revision [DSM-IV-
TR], sex, age), number of children and/or adolescents
investigated, measuring methods used to assess the
incidence of EPS, dose of aripiprazole, and the incidence
of EPS and its manifestations. We contacted the authors
of identified studies via e-mail to obtain unpublished
data.
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2.5 Statistical Analysis
We performed a meta-analysis based on the available
studies described above to obtain an optimal estimation of
the incidence of EPS in children and adolescents treated
with aripiprazole. The effect size used for the incidence of
EPS was the proportion, but all analyses were performed,
converting proportions into logits. Logits are preferred over
proportions because the mean proportion across studies
underestimates the size of the confidence interval (CI)
around the mean proportion (due to the compression of the
standard error as p approaches 0 or 1) and overestimates
the degree of heterogeneity across effect sizes [16]. Lipsey
and Wilson [16] note this is especially the case when the
observed proportions are\0.2 or[0.80, as was the case in
some of the included studies. The logit method circumvents
these problems and is the preferred method. However, for
ease of interpretation, we converted all final results back
into proportions.
We used a Q-statistic to examine the homogeneity of the
effect size distribution [17]. When we observed hetero-
geneity in effect sizes, we assessed the possible influence
of moderator variables (age and sex of study population,
aripiprazole dose, study duration, and tools used to detect
EPS) and evaluated the suitability of either a fixed, random,
or mixed model.
We included study duration as a categorical variable:
short duration (B12 weeks), medium duration ([13 and
\26 weeks), and long duration (C26 weeks).
We used measurement data to develop a binary variable
(making use of history taking and clinical examination with
or without conducting additional questionnaires). The
included studies used a range of different questionnaires:
the Simpson Angus Scale (SAS) [18], the Abnormal
Involuntary Movement Scale (AIMS) [19], the Extrapyra-
midal Symptom Rating Scale (ESRS) [20], the Barnes
Akathisia Rating Scale (BARS) [21], the Udvalg for Kli-
niske Undersøgelser side effect rating scale (UKU) [22],
the Treatment Emergent Symptoms Scale (TESS) [78],
and/or the Safety Monitoring Uniform Research Form
(SMURF) [23]. The AIMS is used to detect the presence of
‘tardive dyskinesia’, a rather late-appearing manifestation
of EPS [10].
Furthermore, we conducted a subgroup analysis to
compare the incidence of EPS and of several EPS mani-
festations (dystonia, akathisia, parkinsonism, tremor, and
tardive dyskinesia) in the included placebo-controlled trials
[24–31]. We chose to omit the study by Findling et al. [74]
from this subgroup analysis because no clear distinction in
observed adverse events between the placebo group and the
aripiprazole group could be made. The authors themselves
acknowledged that ‘‘potentially a portion of the adverse
events observed in the placebo arm may stem from residual
exposure to aripiprazole in phase 1’’ [74].
We calculated effect sizes as the natural logarithm of the
odds ratios (ORs) but converted the mean and CIs back into
ORs to report the final results.
If we could not calculate an OR in some studies because
certain frequencies were equal to zero, we added 0.5 to
these ‘zero frequencies’ to facilitate a calculation of the
OR. This procedure may lead to an underestimation of the
effect size, but it gives an acceptable estimate of the effect
size if the number of ‘zero frequencies’ is low [32].
3 Results
An initial search via PubMed and Embase yielded 328 hits
(53 hits in PubMed and 297 hits in Embase; 22 duplicates).
Consistent with the above-mentioned inclusion and exclu-
sion criteria, we excluded 151 records according to title
and/or abstract and 104 records because of study design
and/or unrelated PICOS structure. We further evaluated all
73 potentially relevant full-text articles in detail and
excluded an additional 34 publications. Manual search of
the reference lists of review papers identified an additional
seven relevant articles. We included 46 publications in the
analysis, but not all studies had data that could be used in
the meta-analysis (see Fig. 1) [24–31, 33–37, 43,
45, 46, 48–77]. See the ESM for a list of the excluded
studies (according to study design and/or unrelated PICOS
structure). We did not restrict our search to studies
assessing oral aripiprazole; however, no studies assessed
the long-acting injectable formulation of the drug in par-
ticipants aged\18 years.
All of the nine included randomized controlled trials
[24–31, 74] had a Jadad score C3 and were considered to
be of adequate trial quality (see Table S2 in the ESM).
The overall methodological quality of the included non-
randomized studies (retrospective chart reviews
[34, 36, 48, 50, 52, 63, 67]; other non-randomized studies
[33, 35, 37, 43, 45, 46, 49, 51, 53–62, 64–66,
68, 73, 75, 76]) was low to moderate (see Table S3 in the
ESM).
The meta-analysis includes 41 studies
[24–31, 33–37, 43, 45, 46, 48–68, 73–76], with a total of
2114 pediatric patients (see Table S1 in the ESM). Of the
41 studies included, 37 [24–31, 33–37, 43, 45, 46,
48–59, 62, 65–68, 73–76] described the mean age of the
participants. The weighted average age was 11.7 years,
with a few outliers: Findling and colleagues [26, 33]
focused on participants aged 4–9 years, Bildik et al. [34]
focused on adolescents aged 15–19 years, and the mean age
in the study by Woods et al. [35] was 17.1 years.
C. Bernagie et al.
A total of 72 % of participants were male. The popu-
lation of most studies consisted mainly of boys, except
those of Bildik et al. [34], Gibson et al. [36], and Tra-
montina et al. [30].
For the analysis of the mean EPS incidence, data were
provided by 24 studies (N), with a total of 1446 pediatric
patients (n) [25, 27–30, 33, 36, 37, 43, 45,
49–51, 53–56, 58, 60, 61, 63, 65, 68, 74]. Meta-analysis
revealed a mean EPS incidence of 17.1 % (95 % CI
0.128–0.223) (Table 1). We calculated the incidence of
akathisia in 24 trials, with 1660 patients [24–31,
33–36, 46, 48, 52, 54, 55, 57, 58, 64, 66, 68, 73, 75]. Meta-
analysis revealed a mean akathisia incidence of 8.8 % (95
% CI 0.059–0.130). The mean incidence of dystonia,
parkinsonism, tremor, and tardive dyskinesia could only be
analysed in a smaller group of patients because available
data were limited. The mean incidence of tardive dyski-
nesia was 1.7 % (95 % CI 0.010–0.028; N = 15, n = 1261)
[24–27, 30, 33, 34, 46, 55, 56, 58, 65, 67, 68, 73], the mean
incidence of tremor was 10.5 % (95 % CI 0.065–0.165; N =
17, n = 1055) [24, 28–30, 34, 48, 50, 55–59, 62, 65,
66, 68, 76], the mean incidence of dystonia was 4.8 % (95
% CI 0.026–0.087; N = 11, n = 785) [24, 25, 27, 29,
31, 34, 46, 48, 55, 64, 68], and the mean incidence of
parkinsonism was 20.8 % (95 % CI 0.159–0.269; N = 10,
n = 755) [24, 25, 27, 45, 46, 52, 55, 56, 68, 73].
Table 1 shows the effect sizes and 95 % CIs (in per-
centages) of the incidence of EPS, its three main categories
(dystonia, akathisia, and parkinsonism), tremor, and tardive
dyskinesia (in the total sample as well as in the subgroup of
placebo-controlled trials).
The Q-statistic showed that variability in effect size
between the studies was higher than would be expected on
the basis of sampling error, for the analysis of both the
incidence of EPS and that of dystonia, akathisia, parkin-
sonism, and tremor. For these extrapyramidal side effects,
we assessed the possible influence of moderator variables
(age and sex of study population, aripiprazole dose, study
duration, and tools to detect EPS). In terms of incidence of
various extrapyramidal side effects, overall, no significant
effects of age, sex, mean dose, study duration, or measur-
ing method could be demonstrated.
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Table 2 represents the comparison between the incidence
of EPS, dystonia, akathisia, parkinsonism, tremor, and tardive
dyskinesia in the placebo-controlled trials. The results are
presented as ORs of aripiprazole versus placebo. Only the
side effects ‘EPS’, ‘parkinsonism’, and ‘tremor’ were signif-
icantly more common in children and adolescents treated with
aripiprazole than in those receiving placebo. The Q-statistic
did not show heterogeneity for any of these side effects, but
the small number of trials mean this can be unreliable.
The funnel plot (Fig. 2) illustrates that studies with a
lower incidence of EPS are over-represented in our anal-
ysis, which may indicate publication bias. There was also
one positive outlier (Lyon et al. [37]). Figure 3 presents the
mean incidence of EPS in children and adolescents treated
with aripiprazole (17 %; 95 % CI 0.13–0.22) as a forest
plot. The mean incidences of the three main categories of
EPS are also displayed graphically (Figs. S1–3 in the
ESM).
4 Discussion
The primary objective of this analysis was to assess the
evidence for (acute) EPS associated with the use of arip-
iprazole in children and adolescents given the assumed
favorable side-effect profile of atypical antipsychotics as a
group relative to typical antipsychotics [5]. Within the
group of atypical antipsychotics, aripiprazole is considered
to lead to relatively minimal metabolic side effects and
prolactin increases [3, 4, 8, 11, 13]. Does the same apply to
the extrapyramidal side effects? Some authors suggest a
lower risk of EPS for certain atypical antipsychotics.
Studies showed a lower risk of emerging EPS in patients
treated with quetiapine or clozapine and a higher risk with
ziprasidone, olanzapine, aripiprazole, and risperidone
[4, 11, 38, 39].
This study reveals that the incidence of EPS in children
and adolescents treated with aripiprazole is not negligible.
Our meta-analysis indicates a mean EPS incidence of
17.1 %. The summary of the European Public Assessment
Report (EPAR) for Abilify (aripiprazole) notes incidence
figures in pediatric patients in line with our findings. These
figures are based on individual studies [1].
Table 1 Effect sizes and 95 % confidence intervals
Extrapyramidal side effect Model Studies
(N)
Point estimate,
% (95 % CI)
EPS Random 24 17.1 (12.8–22.3)
EPS (PCT) Fixed 5 26.3 (22.8–30.2)
Random 5 25.5 (19.0–31.0)
Dystonia Random 11 4.8 (2.6–8.7)
Dystonia (PCT) Fixed 5 3.5 (2.3–5.4)
Random 5 3.5 (2.3–5.4)
Akathisia Random 24 8.8 (5.9–13.0)
Akathisia (PCT) Fixed 8 9.4 (7.5–11.9)
Random 8 7.6 (4.8–11.9)
Parkinsonism Random 10 20.8 (15.9–26.9)
Parkinsonism (PCT) Fixed 3 22 (18.7–25.7)
Random 3 22 (18.7–25.7)
Tremor Random 17 10.5 (6.5–16.5)
Tremor (PCT) Fixed 4 10.5 (7.8–14)
Random 4 12.4 (6.1–23.8)
Tardive dyskinesia Random 15 1.7 (0.10–2.8)
Tardive dyskinesia (PCT) Fixed 5 1.2 (0.6–2.6)
Random 5 1.2 (0.6–2.6)
CI confidence interval, EPS extrapyramidal symptoms, PCT subgroup
analysis of the placebo-controlled trials
Table 2 Comparison between the incidences of extrapyramidal symptoms in the placebo-controlled trails: odds ratios
Model Studies (n) Point estimate
(95 % CI)
Z p value Q-statistic p value Q-statistic
EPS Fixed 5 3.85 (2.37–6.28) 5.42 0.00 4.04 0.40
Random 5 3.85 (2.36–6.30) 5.37 0.00
Dystonia Fixed 5 1.35 (0.52–3.48) 0.61 0.54 3.80 0.43
Random 5 1.35 (0.52–3.48) 0.61 0.54
Akathisia Fixed 8 1.38 (0.77–2.47) 1.07 0.29 13.05 0.07
Random 8 1.29 (0.54–3.12) 0.57 0.57
Parkinsonism Fixed 3 4.91 (2.76–8.75) 5.40 0.00 0.58 0.75
Random 3 4.91 (2.76–8.75) 5.40 0.00
Tremor Fixed 4 3.46 (1.42–8.43) 2.73 0.01 1.97 0.58
Random 4 3.46 (1.42–8.43) 2.73 0.01
Tardive dyskinesia Fixed 5 1.92 (0.43–8.59) 0.85 0.39 0.37 0.99
Random 5 1.92 (0.43–8.59) 0.85 0.39
CI confidence interval, EPS extrapyramidal symptoms
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Ching and Pringsheim [40] undertook a Cochrane
review and also suggested a higher percentage of EPS in
children and adolescents with autism spectrum disorders
treated with aripiprazole than in those receiving placebo
(risk ratio 1.8; 95 % CI 0.98–3.66; P = 0.06). It is possible
that the result did not reach statistical significance because
of a lack of power with only two included studies.
Children and adolescents seem to be as sensitive as
adults to developing EPS when treated with aripiprazole.
The Abilify summary of product characteristics reports an
EPS incidence of 18.2–26.6 % in adult patients with a
manic episode of a bipolar I disorder and 14.8–25.8 % in
adult patients with schizophrenia. These figures are also
based on individual studies [1].
In contrast, some authors note a higher sensitivity in the
pediatric population for the development of EPS under
treatment with (atypical) antipsychotics [12]. Differences in
pharmacokinetics, in dopaminergic receptor density (which
is inversely proportional to age), and pharmacodynamics
have been suggested as possible explanations [38, 41]. The
-4 -3 -2 -1 0 1 2 3 4
0,0
0,5
1,0
1,5
2,0
St
an
da
rd
 E
rr
or
Logit event rate
Funnel Plot of Standard Error by Logit event rateFig. 2 Asymmetric funnel plot
of the included studies
Model Study name Statistics for each study Event rate and 95% CI
Event Lower Upper 
rate limit limit Z-Value p-Value
Findling, 2009 (b) [25] 0,315 0,254 0,383 -5,072 0,000
Marcus, 2011 [58] 0,145 0,111 0,188 -11,341 0,000
Findling, 2013 [27] 0,274 0,208 0,352 -5,252 0,000
Marcus, 2009 [28] 0,224 0,167 0,294 -6,649 0,000
Sanna, 2013 [63] 0,464 0,292 0,646 -0,378 0,706
Stigler, 2009 [65] 0,360 0,199 0,560 -1,381 0,167
Owen, 2009 [29] 0,149 0,073 0,281 -4,254 0,000
Yoo, 2011 [43] 0,194 0,090 0,369 -3,139 0,002
Gibson, 2007 [36] 0,133 0,061 0,267 -4,268 0,000
Findling, 2009 (a) [56] 0,217 0,093 0,428 -2,534 0,011
Findling, 2011 [33] 0,052 0,022 0,119 -6,317 0,000
Findling, 2008 (a) [55] 0,217 0,093 0,428 -2,534 0,011
Yoo, 2007 [68] 0,167 0,064 0,369 -2,938 0,003
Rani, 2009 [61] 0,071 0,027 0,175 -4,943 0,000
Findling, 2014 [74] 0,073 0,024 0,204 -4,234 0,000
Bastiaens, 2009 [49] 0,100 0,025 0,324 -2,948 0,003
Tramontina, 2009 [30] 0,111 0,028 0,352 -2,773 0,006
Biederman, 2007 [51] 0,105 0,026 0,337 -2,863 0,004
Biederman, 2005 [50] 0,024 0,003 0,154 -3,644 0,000
Murphey, 2009 [45] 0,063 0,009 0,335 -2,622 0,009
Erickson, 2011 [54] 0,038 0,002 0,403 -2,232 0,026
Ramos-Rios, 2009 [60] 0,038 0,002 0,403 -2,232 0,026
Ercan, 2012 [53] 0,024 0,001 0,287 -2,594 0,009
000,0489,81-132,0681,0802,0dexiF
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Fig. 3 Forest plot of the mean
incidence of extrapyramidal
symptoms in children and
adolescents treated with
aripiprazole without the positive
outlier. CI confidence interval
Acute EPS in Minors Using Aripiprazole
EPAR summary [1] describes a higher risk of developing
acute dystonia in younger age groups, particularly with
aripiprazole. Our analysis did not reveal a significant effect
of age on the various extrapyramidal side effects.
The meta-analysis by Cohen et al. [4] revealed a sig-
nificant increase in EPS in children and adolescents treated
with atypical antipsychotics versus placebo, except for
quetiapine, noting the following ORs: ziprasidone (20.56;
95 % credible interval [CrI] 3.53–68.94), olanzapine (OR
6.36; 95 % CrI 2.43–13.84), aripiprazole (OR 3.79; 95 %
CrI 2.17–6.17), risperidone (OR 3.71; 95 % CrI 2.18–6.02),
and quetiapine (OR 2.54; 95 % CrI 0.88–6.07). The anal-
ysis did not include clozapine.
These findings are in accordance with our data. We
conducted a subgroup analysis of the included placebo-
controlled trials to compare the incidence of EPS. Arip-
iprazole significantly increased the risk of EPS (OR 3.85;
95 % CI 2.37–6.28). Although aripiprazole is supposed to
lead to relatively minimal metabolic side effects and pro-
lactin increases [3, 4, 8, 11, 13], the risk of extrapyramidal
side effects seems to be in line with that of other atypical
antipsychotics (e.g., risperidone).
Kumar et al. [42] reported on the efficacy and tolera-
bility of atypical antipsychotics in adolescents with psy-
chosis. Only one included study compared the incidence of
(acute) EPS between patients treated with an atypical
antipsychotic (risperidone) and those treated with a typical
antipsychotic (perphenazine) (risk ratio 0.37; 95 % CI
0.20–0.68). Furthermore, only one study [43] in our anal-
ysis compared treatment with an atypical antipsychotic
(aripiprazole) with treatment with a typical antipsychotic
(haloperidol) (OR 0.343; 95 % CI 0.092–1.276).
In terms of the incidence of the various extrapyramidal
side effects, we found no significant effects of the other
moderator variables (sex, mean dose, study duration, and
measuring method), despite (sporadic) suggestive findings
in literature. For example, the EPAR summary [1] suggests
that men have a higher risk of developing acute dystonia.
Argyriou et al. [44] and EMA [1] mention a positive dose–
response relationship in children and adolescents: a higher
dose of aripiprazole is supposed to increase the incidence
of EPS. For this reason, the FDA [2] recommends a daily
dose of 10 mg (with a maximum of 30 mg/day). In our
analysis, the mean daily doses ranged between 3.3 [45] and
24.52 mg [46]. We found no daily intakes of 30 mg, which
possibly led to the lack of a potential dose–response rela-
tionship in our analysis. Moreover, most of the included
trials used flexible dosing. Only a fixed- and multiple-dose
study can address the issue of the dose relationship with
outcome. Further research is recommended.
Since the Q-statistic did not reveal heterogeneity, we did
not assess the possible influence of any moderator variable
on the incidence of tardive dyskinesia. A possible
explanation could be the small number of trials, which
makes the Q-statistic unreliable.
Overall, the severity of EPS was described as mild to
moderate, transient, and treatable (if necessary). EPS can
be screened for in several ways, which is reflected in the
non-uniform registration of EPS in the different study
populations. One method of screening is assisted self-re-
porting by parents/children, or—preferably—a combina-
tion of both. When no input from the child is possible, the
child’s guardian is surveyed; this only happened in
exceptional situations. A second option to screen for EPS is
by (hetero-)anamnesis. The researcher could explicitly ask
for the occurrence of EPS in its various manifestations. A
supplementary clinical neurological examination could be
conducted. Particular attention should be given to the fol-
lowing: mental status, cranial nerves, motor examination,
coordination and gait, and a general observation of the
patient (e.g., ‘‘are abnormal movements noted?’’) [47].
Some structured questionnaires, such as the BARS [21] and
the ESRS [20], consist of (hetero)-anamnesis and a clinical
neurological examination combined. It is important to
highlight that the SAS [18], the ESRS [20], the BARS [21],
and the AIMS [19] have been neither validated nor
developed specifically for pediatric use [47]. This is why
Correll et al. [38] suggest use of the SMURF [23], a
standardized pediatric side-effect scale. Based on these
questionnaires, researchers can screen for EPS in a struc-
tured way and may qualify and quantify the retrieved EPS
whereby severity can be assessed.
4.1 Limitations
Most of the limitations are linked to the nature of the
included studies. First, the definition of extrapyramidal side
effects varies across studies. This could be because of the
various screening methods used to detect EPS. In addition
to (hetero)-anamnesis and clinical neurological examina-
tion, one or more structured questionnaires are often used.
The SAS [18], the BARS [21], and the AIMS [19] are the
most common, but other questionnaires and multiple
combinations thereof are also used. More specifically, the
symptom ‘tremor’ can be defined in different ways.
Although tremor can be a symptom of medication-induced
parkinsonism, a (fine) tremor can also arise when a subject
tries to maintain a certain position (‘medication-induced
postural tremor’, no manifestation of EPS) [10]. With a few
exceptions, this distinction was not described.
Second, many of the included studies allowed the use of
concomitant medication (e.g., anticholinergics). Because of
the inconsistent reporting, we were unable to assess the
influence of this possiblemoderator variable. The same applies
to the reporting of participant drug history (e.g., antipsychotic
naı¨ve or not), which may have affected our results.
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Another limitation is that a well-defined length of
exposure to aripiprazole was lacking, with many studies
mentioning only study duration. The influence of this
possible moderator variable could not be assessed.
Most of the included studies were short in duration.
Therefore, we were unable to explore any possible long-
term side effects, despite our concern about the impact this
drug can exert on the developing brain as it targets the
transmitter pathways in the central nervous system [38].
Next, the majority of included studies had small study
populations, limiting their power. In fact, the overall
lower quality of the included studies is an important
limitation. Study design was very heterogeneous (retro-
spective vs. prospective, randomized vs. not, with or
without a control group, placebo controlled vs. active
comparator controlled, etc.), as was their internal validity.
Head-to-head comparisons of the different antipsychotics
were rare.
Finally, the methodology of our literature review and
meta-analysis include some further inherent limitations.
First, only on researcher performed both the selection of
studies and the assessment of methodological quality.
Second, a selection bias may have been introduced with the
exclusion of studies. The possibility of publication bias
must also be taken into account, because studies with a
lower incidence of EPS were over-represented in our
analysis. It is possible that the found mean incidence of
EPS in children and adolescents treated with aripiprazole is
underestimated.
5 Conclusion
In recent years, the use of aripiprazole in youth, for both
official and off-label indications (anxiety, eating, person-
ality disorders, Gilles de la Tourette syndrome, etc.) [14],
has increased because of the perceived favorable risk
profile. However, the assumed favorable side-effect profile
of atypical antipsychotics as a group relative to the typical
antipsychotics has recently been questioned [9, 13]. Our
meta-analysis supports these recent concerns, as it reveals a
mean EPS incidence in children and adolescents treated
with aripiprazole of 17.1 % (95 % CI 0.128–0.223). This
finding highlights the importance of further research in this
field, especially considering the significance of how neg-
atively EPS can impact patient quality of life (e.g., through
stigmatization, stress and anxiety, and potentially life-
threatening events, for example the emergence of laryn-
gospasm) [3]. Randomized, (double) blinded, placebo-
controlled/multi-arm, head-to-head comparator studies
with long-term follow-up and large study populations with
subjects of both sexes are urgently needed. Furthermore, a
more precise definition and operationalization of the
concept of EPS and of its measurement is necessary. The
research setting should mimic a clinical setting as closely
as possible. This may lead to the identification of potential
risk factors in specific subsets of pediatric patients with the
aim of predicting and even preventing the onset of
extrapyramidal side effects from treatment with atypical
antipsychotics (including aripiprazole).
Each antipsychotic has a unique profile of (side) effects.
Besides the risk of the onset of EPS, the risk of emerging
metabolic side effects and hyperprolactinemia also plays an
important role in the choice of therapy. Atypical antipsy-
chotics should be prescribed with caution in children and
adolescents. Hopefully, in the near future, our findings and
further research will provide more individualized guideli-
nes to assist clinicians, together with the patient and
guardians, to make well-balanced treatment choices.
In addition, given the non-negligible incidence of EPS
found in our analysis, clinicians are urged to undertake
more targeted medication monitoring in clinical practice.
For example, we recommend using the SMURF [23], a
standardized pediatric side-effect scale.
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